Rapid Reports

Biochemical Characterization of the HpxO Enzyme from *Klebsiella pneumoniae*, a Novel FAD-Dependent Urate Oxidase[†]

Seán E. O'Leary, Katherine A. Hicks, Steven E. Ealick,* and Tadhg P. Begley*

Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853-1301

Received January 30, 2009; Revised Manuscript Received February 27, 2009

ABSTRACT: The HpxO enzyme from *Klebsiella pneumoniae* was recently proposed, on the basis of genetic studies, to catalyze the hydroxylation of uric acid to 5-hydroxyisourate as part of the purine catabolic pathway. Its primary sequence suggests that the HpxO catalytic activity depends on a flavin cofactor (FAD), contrasting with all previously studied urate oxidase enzymes, which have no cofactor requirement. Here we demonstrate biochemically that HpxO is an FAD-dependent urate oxidase. Our data are consistent with the proposal that HpxO-bound flavin hydroperoxide is the hydroxylating species. These results confirm the existence of a novel mechanistic paradigm in purine catabolism.

Catabolism of purine nucleobases is an important mechanism for nitrogen assimilation by many organisms when their growth is limited by the availability of ammonia or alternative nitrogen sources (*1*). The bases are converted to hypoxanthine **1** or xanthine **2** and then oxidized to uric acid **3** (Figure 1A). The steps to this point are ubiquitous in Nature, but humans, among other organisms, lack the ability to metabolize urate to allantoin **6** (*2*). In contrast, the pathway from urate, in a variety of microbes and plants, has been intensively studied and proceeds under aerobic conditions in three steps from urate to allantoin **6**. The first step is the hydroxylation of urate, catalyzed by urate oxidase (*1, 3*). In all previously studied cases, the catalytic mechanism of urate oxidase is remarkable in that it does not require a cofactor (*4*). Detailed studies have implicated the electron-rich urate dianion as an enzyme-bound intermediate which can react spontaneously with molecular oxygen in its triplet ground state, forming a peroxide intermediate. Analogy has thus been made between urate and the isoalloxazine moiety of flavins which in its reduced form undergoes a similar oxidation. In extension of the analogy, EPR spin trapping experiments have suggested the presence of transient radical intermediates in the steps leading to the urate hydroperoxide intermediate (*5*).

The urate oxidase product, 5-HIU **4**, is unstable in aqueous buffer, hydrolyzing spontaneously to 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU)[1] **5** (*6*). Notwithstanding the operation of this spontaneous reaction under physiological conditions, all known organisms which express the cofactorless urate oxidase also possess a hydrolase enzyme which accelerates the conversion of **4** to **5**. The decarboxylation of OHCU **5** to allantoin **6** is also spontaneous under physiological conditions but nonenzymatically produces racemic allantoin (*3a*). A stereospecific decarboxylating enzyme, which produces only (*S*)-allantoin, is found in organisms with urate oxidase and 5-HIU hydrolase (*7*); some organisms also possess a racemase enzyme (*1, 8*). Allantoin can be further catabolized to ammonia and carbon dioxide, thus utilizing the remaining nitrogen atoms in the imidazoline ring (*1, 9*).

While the enzymology of the pathway outlined above has been thoroughly investigated, two very recent reports (*10*) have suggested that the pathway from hypoxanthine to allantoin, involving the same intermediates but different catalytic strategies for their interconversion, exists in the facultative anaerobe *Klebsiella pneumoniae*, a ubiquitous human pathogen (*11*). In particular, the enzyme proposed to catalyze the conversion of urate to 5-hydroxyisourate **4** shows sequence similarity to FAD-dependent monooxygenases catalyzing the hydroxylation of aromatic compounds. It was noted that the enzyme sequence includes residues which are conserved across this group of enzymes that contain an FAD-binding domain and a small NADH-binding domain (Figure S1 of the Supporting Information) (*12*). Both reports proposed that HpxO catalyzes the hydroxylation of urate by a mechanism similar to that of the well-studied *p*-hydroxybenzoate hydroxylase (*13*) and that HpxO is the first example of an FAD-dependent urate oxidase. However, de la Riva et al. also reported that in their study, cells with *hpxO*, expressed from a high-copy plasmid, lacked discernible urate oxidase activity (*10b*).

To test the prediction that HpxO is an FAD-dependent urate oxidase, we cloned, heterologously overexpressed, and purified the recombinant, N-terminally His$_6$-tagged protein (see the Supporting Information for details) and then reconstituted its activity *in vitro*. The isolated protein was more than 95% pure, as determined by SDS–PAGE analysis (Figure 1B), with a molecular mass (including the N-terminal

[1] Abbreviations: EDTA, ethylenediaminetetraacetic acid; EPR, electron paramagnetic resonance; FAD, flavin adenine dinucleotide; 5-HIU, 5-hydroxyisouric acid; UA, uric acid; NAD(P)H, reduced *β*-nicotinamide adenine dinucleotide (phosphate); NAD(P)$^+$, *β*-nicotinamide adenine dinucleotide (phosphate); Ni-NTA, nickel-nitrilotriacetic acid; OHCU, 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline.

FIGURE 1: Isolation of *Klebsiella pneumoniae* HpxO. The recombinant enzyme with an N-terminal His$_6$ tag was overexpressed in *Escherichia coli* BL21(DE3) using standard protocols. The enzyme was purified by Ni^{2+}-nitrilotriacetic acid chromatography. (A) Purine catabolic pathway from hypoxanthine to allantoin. HpxO catalyzes hydroxylation of urate **3** to the unstable 5-hydroxyisourate **4**, which is converted both enzymatically and nonenzymatically via 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) **5** to allantoin **6**. (B) SDS−PAGE analysis (12% acrylamide) of the purified enzyme. The molecular mass was ∼45 kDa, including the affinity tag. (C) UV−visible spectrum of HpxO, with absorbance maxima at 454, 381, 273, and <220 nm. (D) Reverse-phase (C$_{18}$) HPLC analysis of the small molecule released from HpxO on heat denaturation. Absorbance was detected at 250 nm. The mobile phase consisted of a gradient from 0 to 65% methanol in potassium phosphate buffer. A minor impurity (R_T = 15.9 min) present in the commercial sample of FAD (R_T = 14.7 min) was also found in the HpxO-derived sample; the increased proportion of this impurity in the HpxO sample was attributed to the effects of heat denaturation. (E) UV−vis spectrum of the HPLC-purified FAD isolated from heat-denatured HpxO.

tag) of ∼45 kDa. The HpxO protein solution, after gel filtration, was yellow, suggesting the presence of a tightly bound cofactor. The UV−visible spectrum of the protein solution (Figure 1C) had maxima at 454, 381, 273, and <220 nm. Reverse-phase HPLC analysis of the small molecule released from the protein upon heat denaturation confirmed that the cofactor was FAD (Figure 1D,E). We determined the HpxO:FAD stoichiometry by measurement of the FAD-derived absorbance in a solution of HpxO denatured by the addition of urea to a concentration of 6 M. The 450 nm absorbance [ε_{450} = 9.7 mM^{-1} cm^{-1} (Figure S2)] was used to compute the FAD-derived 280 nm absorbance (A_{280}/A_{450} = 1.84), which in turn was subtracted from the total absorbance at 280 nm to give the protein absorbance at that

FIGURE 2: Reverse-phase (C$_{18}$) HPLC analysis of the urate oxidase activity of HpxO. All reactions were performed in 0.1 M potassium phosphate (pH 8.0) at room temperature (∼22 °C). Reaction components, where present, were at the following concentrations: uric acid at 0.1 mM, NADPH at 0.25 mM, HpxO at 0.13 μM, and commercially available urate oxidase (Sigma-Aldrich) from *Candida* sp. at 2.2 units/mL (1 unit is defined as the quantity of enzyme which oxidizes 1.0 μmol of uric acid to allantoin at pH 8.5 and 25 °C). (A) HpxO control reaction without urate. (B) Control without NADPH. (C) Control without HpxO. (D) NADPH-independent reaction of urate catalyzed by urate oxidase from *Candida* sp. (E) HpxO reaction with urate, NADPH, and HpxO. (F) Proposed mechanism for HpxO-catalyzed formation of 5-HIU.

wavelength. The protein absorbance was then used to determine its concentration based on the theoretical HpxO molar extinction coefficient (57.4 mM^{-1} cm^{-1}) at 280 nm (*14*). The FAD concentration and the protein concentration agreed to within 10% and also agreed with the protein concentration determined by the Bradford method (*15*). Taken together, these results suggest that the FAD:HpxO stoichiometry is 1:1.

Having demonstrated that HpxO is a flavoprotein, we investigated its catalytic activity toward uric acid. Treatment of uric acid with HpxO in the presence of NAD(P)H resulted in a decrease in the 340 nm absorbance, consistent with the oxidation of NAD(P)H to NAD(P)$^+$. The rate of this decrease in A_{340} depended linearly on the enzyme concentration and could be saturated at high concentrations of urate or NADH. At saturating concentrations of NADH (1.5 mM; see below), the 385 nm absorbance was monitored (ε_{385} = 0.745 mM^{-1} cm^{-1}). When urate was omitted, there was a detectable, enzyme-dependent rate of NAD(P)H oxidation, but this was not significant relative to the rates observed in the presence of urate. A fit of the kinetic data where NADH was used as the nucleotide cosubstrate to the Michaelis−Menten equation

gave values for K_m and k_{cat} of 42 ± 8 μM and 42 ± 2 s^{-1}, respectively ($k_{cat}/K_m = 1.0 \pm 0.2$ μM^{-1} s^{-1}), for urate (Figure S3). This is similar to that of the cofactor-independent urate oxidase ($k_{cat}/K_m = 0.21$ μM^{-1} s^{-1}). However, HpxO is considerably more efficient with respect to utilization of molecular oxygen. We estimated a K_m value for molecular oxygen of at most $\sim$50 μM (Figure S4) and hence a value for k_{cat}/K_m of at least $\sim$0.7 μM^{-1} s^{-1}, which appears to be at least 1 order of magnitude greater than the equivalent value for the cofactor-independent urate oxidase (0.034 μM^{-1} s^{-1}).

Previous studies on the stability of the proposed HpxO product, 5-HIU **4**, have shown that it should react spontaneously under our assay conditions to form allantoin; full conversion should occur in $\sim$1 h. HPLC analysis of samples of urate, incubated with HpxO for 1 h in the presence of NADPH followed by removal of the enzyme, confirmed the presence of allantoin and NADP$^+$ (Figure 2E). Assignment of the product as allantoin was confirmed by comparison with an authentic standard and also with the reaction products from a commercially available, FAD-independent urate oxidase (Figure 2D). Control experiments from which urate was omitted confirmed that HpxO can catalyze the slow conversion of NADPH to NADP$^+$ in the absence of urate (Figure 2A−C). These results suggest 5-HIU **4** to be the immediate product of the HpxO-catalyzed reaction. This proposal is further supported by the presence of genes in the *hpx* cluster which are proposed to encode 5-HIU hydrolase and OHCU decarboxylase. Analysis of the time course of the HpxO-catalyzed reaction from uric acid to allantoin by UV−visible spectrophotometry also indicated that 5-HIU and OHCU accumulated and decayed on the expected time scales (Figure S5).

HpxO shows selectivity (*V/K* ratio of $\sim$10) for NADH over NADPH. The HpxO steady-state rate showed no saturation at concentrations of NADPH up to 1 mM, suggesting this value as a lower limit for $K_{m,NADPH}$. A linear fit to the rate−concentration data gave an estimate of 9.7 ± 0.3 mM^{-1} s^{-1} for the k_{cat}/K_m value (Figure S6A). In contrast, the steady-state rate exhibited saturation at NADH concentrations above 0.5 mM, and a hyperbolic fit to this data gave 125 ± 30 mM^{-1} s^{-1} as an estimate of $k_{cat,NADH}/K_{m,NADH}$ (Figure S6B).

We also sought to demonstrate the formation of the dihydroflavin intermediate **8** by the reaction of NADPH with HpxO under anaerobic conditions. HpxO was incubated in the presence of glucose, glucose oxidase, and catalase for 15 min in a sealed spectrophotometer cuvette prior to the introduction of an excess of NADPH. The absorbance spectrum in the 400−550 nm region was recorded after a further incubation of 10 min to allow for consumption of residual oxygen. The spectrum showed complete removal of the 454 nm-centered absorbance, consistent with the formation of dihydro-FAD **8** (Figure S7). Considered along with the evidence that molecular oxygen is a substrate and the precedent available from previously well-studied systems,

this result suggests that the mechanism presented in Figure 2F is in operation during the HpxO catalytic cycle.

In summary, we have confirmed the recent proposals that HpxO is an FAD-dependent urate hydroxylase. The reaction produces 5-hydroxyisourate which is spontaneously converted to allantoin in two nonenzymatic steps. Our data suggest a mechanism for urate hydroxylation similar to that observed for the well-studied *p*-hydroxybenzoate hydroxylase. The results illustrate a previously uncharacterized mechanistic motif for urate oxidation and thus for microbial purine metabolism.

SUPPORTING INFORMATION AVAILABLE

Details of the molecular cloning, experimental procedures, and Figures S1−S7. This material is available free of charge via the Internet at http://pubs.acs.org.

REFERENCES

1. (a) Vogels, G. D., and van der Drift, C. (1976) *Bacteriol. Rev. 40*, 403–468. (b) Brondino, C., Romão, M. J., Moura, I., and Moura, J. J. G. (2006) *Curr. Opin. Chem. Biol. 10*, 109–114.
2. Oda, M., Satta, Y., Takenaka, O., and Takenaka, N. (2002) *Mol. Biol. Evol. 19*, 640–653.
3. (a) Kahn, K., Serfozo, P., and Tipton, P. A. (1997) *J. Am. Chem. Soc. 119*, 5435–5442. (b) Imhoff, R., Power, N. P., Borrok, M. J., and Tipton, P. A. (2003) *Biochemistry 42*, 4094–4100.
4. Kahn, K., and Tipton, P. A. (1997) *Biochemistry 36*, 4731–4738.
5. Busi, E., Terzuoli, L., Basosi, R., Porcelli, B., and Marinello, E. (2004) *Nucleosides, Nucleotides Nucleic Acids 23*, 1131–1134.
6. Ramazzina, I., Folli, C., Secchi, A., Berni, R., and Percudani, R. (2006) *Nat. Chem. Biol. 2*, 144–148.
7. (a) Kim, K., Park, J., and Rhee, S. (2007) *J. Biol. Chem. 282*, 23457–23464. (b) Cendron, L., Berni, R., Folli, C., Ramazzina, I., Percudani, R., and Zanotti, G. (2007) *J. Biol. Chem. 282*, 18182–18189.
8. van der Drift, L., Vogels, G. D., and van der Drift, C. (1975) *Biochim. Biophys. Acta 391*, 240–248.
9. Mulrooney, S. B., and Hausinger, R. P. (2003) *J. Bacteriol. 185* (1), 126–134.
10. (a) Pope, S. D., Chen, L.-L., and Stewart, V. (2009) *J. Bacteriol. 191*, 1006–1017. (b) de la Riva, L., Badia, J., Aguilar, J., Bender, R. A., and Baldoma, L. (2008) *J. Bacteriol. 190* (24), 7892–7903.
11. (a) Podschun, R., and Ullmann, U. (1998) *Clin. Microbiol. Rev. 11* (4), 589–603. (b) Keynan, Y., and Rubinstein, E. (2007) *Int. J. Antimicrob. Agents 30* (5), 385–389.
12. Harayama, S., Kok, M., and Neidle, E. L. (1992) *Annu. Rev. Microbiol. 46*, 565–601.
13. (a) Ortiz-Maldonado, M., Entsch, B., and Ballou, D. P. (2004) *Biochemistry 43*, 15246–15257. (b) Entsch, B., and van Berkel, W. J. H. (1995) *FASEB J. 9*, 476–483.
14. Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., and Gray, T. (1995) *Protein Sci. 4*, 2411–2423.
15. Bradford, M. M. (1976) *Anal. Biochem. 131*, 248–254.

BI900160B